CLOSE

Dialog Box

Loading...

Current Australian Clinical Trials related to Neuroendocrine Cancers

 

Lutetium-177 OPS-201 for Progressive Metastatic Neuroendocrine Tumours

Official Title:      An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

The purpose of this clinical phase I/II study is to investigate the safety and tolerability of 177Lu-OPS201 used for the treatment of patients with neuroendocrine tumours (NETs). Secondary objectives of this study are the assessment of biodistribution, dosimetry and preliminary efficacy of 177Lu-OPS201.

Contact for trial:
Theranostics Australia +618 9091 1081 or email reception@theranostics.com.au
 
Australian sites recruiting:
WA - Ramsay Hollywood Private Hospital, Dept of Nuclear Medicine
VIC - Peter MacCallum Cancer Centre, Molecular Imaging and Targeted Therapeutics Laboratory

FOr more information on this trial, please click here

 

Merkel Cell Carcinoma (MCC)

Trial Name : Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Official Title:      A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma

Australian Sites Recruting:  

      VIC:    Peter MacCallum Cancer Centre - Dr Sandhu
      NSW: Royal North Shore Hospital - Dr Guminski
                Port Macquarie Hospital - Dr Begbie QLD: PAH, Dr Atkinson
      QLD: Saint John of God (Subiaco) - Dr van Hagen

For more information on this trial please click here

 

Neuroendocrine Carcinoma (NEC)

Title: A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As 
First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas (NABNEC Study)

Scientific Title: A phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas.

The primary purpose of this trial is to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with carboplatin plus etoposide chemotherapy for the treatment of gastrointestinal neuroendocrine carcinomas (NECs).

Contact person for trial: 
Dr Mustafa Khasraw
NHMRC Clinical Trials Centre The University of Sydney Locked Bag 77 Camperdown NSW 1450
+61 2 9562 5000  

For more information on this trial click here .To watch a short video see below:

Mid Gut NETs (mNETS) and Pancreatic NETs (pNETs)

Title: CONTROL NETs - Capecitabine ON Temozolomide Radionuclide therapy Octreotate Lutetium177 NeuroEndocrine Tumors Study

The ultimate goal of CONTROL NETs is to improve outcomes for patients with advanced GI/2 NETs. The primary endpoint is progression free survival (PFS).  Secondary endpoints include objective tumour response rate (OTRR), overall survival (OS,) safety, resource utilization and quality of life (QoL). 

Contact person for trial: 
CONTROL NETs Trial Coordinator
NHMRC Clinical Trials Centre The University of Sydney Locked Bag 77 Camperdown NSW 1450
p: +61 2 9562 5000 

e: mailto:controlnets@ctc.usyd.edu.au

Click here for more information on CONTROL NETs 

Gastroenteric and Pancreatic NETs (GEP-NET)

Title: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)

Summary: The purpose of the Phase III study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

Contact person for trial:
Royal North Shore Hospital, NSW
Peter MacCallum Cancer Centre, VIC

For more information on this trial please click here.